Trial Profile

HEALEY ALS Platform Trial - Regimen G DNL343

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 06 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs DNL 343 (Primary)
Indications Amyotrophic lateral sclerosis
Focus Therapeutic Use
Acronyms HEALEY ALS Platform Trial

Most Recent Events

04 Feb 2025 Status changed from active, no longer recruiting to completed.
06 Jan 2025 According to a Denali Therapeutics Inc media release, additional analyses including neurofilament light (NfL) and other fluid biomarkers, prespecified sub-group analyses and analyses from the active treatment extension period are expected later in 2025.
06 Jan 2025 Primary endpoint (Disease Progression) has not been met according to a Denali Therapeutics Inc media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com